DZ Bank
RIGL icon

DZ Bank’s Rigel Pharmaceuticals RIGL Stock Holding History

DZ Bank’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,532
Closed -$280K – 1053
2025
Q4 		$280K Sell
6,532
-11,169
-63% -$421K ﹤0.01% 845
2025
Q3 		$501K Buy
17,701
+8,212
+87% +$246K ﹤0.01% 769
2025
Q2 		$178K Buy
+9,489
New +$180K ﹤0.01% 843
2023
Q2 		– Sell
-182,238
Closed -$2.41M – 1089
2023
Q1 		$2.41M Sell
182,238
-38,204
-17% -$607K ﹤0.01% 559
2022
Q4 		$3.31M Buy
220,442
+146,616
+199% +$1.34M 0.01% 511
2022
Q3 		$871K Buy
+73,826
New +$998K ﹤0.01% 704
2018
Q2 		– Sell
-20,000
Closed -$708K – 1047
2018
Q1 		$708K Buy
+20,000
New +$801K ﹤0.01% 728

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DZ Bank's RIGL Position: Q1 2026 in Review

DZ Bank sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 6,532 shares — an estimated $280K sold.

DZ Bank first reported a position in RIGL in Q1 2018 and held it in 7 quarters. The position peaked at $3.31M in Q4 2022. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • DZ Bank reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • DZ Bank sold 6,532 Rigel Pharmaceuticals shares in Q1 2026, an estimated $280K.
  • DZ Bank first reported a position in Rigel Pharmaceuticals in Q1 2018 and held it in 7 quarters.
  • DZ Bank's Rigel Pharmaceuticals position peaked at $3.31M in Q4 2022.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on DZ Bank's 13F filing for Q1 2026, filed 15 May 2026.